



EMPOWERING DIABETES CARE

In T2DM with CVD/CKD Risk

^{Rx} Diet, Exercise &

AffOEmpa[®] 10/25
Empagliflozin 10/25 mg Tablets



In T2DM with Cardio-Renal Risk

^{Rx} Diet, Exercise &

AffOEmpa[®]-M

5/500
12.5/500
12.5/1000

Empagliflozin 5 mg + Metformin Hydrochloride 500 mg Tablets
Empagliflozin 12.5 mg + Metformin Hydrochloride 500/1000 mg Tablets



In T2DM with CVD/CKD Risk

^R Diet, Exercise &

AffoEmpa[®] 10/25

Empagliflozin 10/25 mg Tablets

In T2DM with Cardio-Renal Risk

^R Diet, Exercise &

AffoEmpa[®]-M

5/500
12.5/500
12.5/1000

Empagliflozin 5 mg + Metformin Hydrochloride 500 mg Tablets
Empagliflozin 12.5 mg + Metformin Hydrochloride 500/1000 mg Tablets

Background:

- As type 2 diabetes progresses, managing HbA1c and preventing complications like heart failure and kidney disease becomes more challenging. Empagliflozin effectively controls blood sugar while reducing body weight, blood pressure, and the risk of cardiovascular and kidney complications. Its low risk of hypoglycemia makes it a safe, long-term solution for diabetes management. When combined with Metformin, Empagliflozin enhances glycemic control, improves insulin sensitivity and reduces hepatic glucose production. Together, they offer a comprehensive approach to managing diabetes, providing better patient outcomes, especially in those with comorbidities like heart failure and kidney disease.

Description:

AffoEmpa:

- Empagliflozin 10 mg & 25 mg Tablets.

AffoEmpa-M:

- Empagliflozin 5 mg + Metformin 500 mg Tablets.
- Empagliflozin 12.5 mg + Metformin 500 mg Tablets.
- Empagliflozin 12.5 mg + Metformin 1000 mg Tablets.

Indications:

- AffoEmpa** : As an adjunct to diet and exercise in T2DM with CVD/CKD Risk
- AffoEmpa-M** : As an adjunct to diet and exercise in T2DM with Cardio-Renal Risk

Mechanism of Action:

Empagliflozin:

- Inhibits SGLT2, blocking glucose reabsorption in the kidneys, increasing urinary glucose excretion, and reducing blood glucose levels. This helps control blood sugar and may lead to weight loss.

Metformin:

- Decreases blood glucose by reducing hepatic glucose production and increases insulin sensitivity to enhance peripheral glucose uptake and utilization.

Dosage:

- AffoEmpa-10/25** : One tablet daily or as prescribed by the doctor
- AffoEmpa-M 5/500** : One tablet daily or as prescribed by the doctor.
- AffoEmpa-M 12.5/500** : One tablet twice daily or as prescribed by the doctor
- AffoEmpa-M 12.5/1000** : One tablet daily or as prescribed by the doctor

References:
1.N Engl J Med 2024;390:1455-1466 | 2.Diabetes Care 2015;38:420-428



Corporate Office & Regd. Office:

1009-1010, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019
Tel.: 011-47589500-51 (50 lines), E-mail: info@medicamenlifesciences.com
Web: www.medicamen.com/lifesciences

I am:

Call me on:

Mail me at: